 | |
| Names | |
|---|---|
| IUPAC name (1S,5R)-8-[Bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| |
| |
| Properties | |
| C28H31NO | |
| Molar mass | 397.562 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
SCH-221510 is an experimental opioid drug. It has potential as an analgesic and as a treatment to addiction of certain drugs.
Most opioid analgesics act throughdelta,mu, andkappa opioid receptors; however, SCH-221510 is instead anagonist at thenociceptin receptor.[1]
Classical opioid analgesics (such as morphine) usually have effects such as constipation, hypoventilation and addiction.[2] However, by acting through a different receptor, SCH-221510 seems to be lacking the undesirable effects of morphine atequianalgesic doses.[1] This suggests that SCH-221510 could be a better opioid than the currently available opioid pain medications, by having less side effects.
SCH-221510 might be an option in the treatment of certain drug addictions: it is able to decrease ethanol self-administration[3] and was able to decrease self-administration ofremifentanil, a fentanyl analogue, in a study,[4]